Is ANI Pharmaceuticals Inc (ANIP) overvalued? · rev $614.4M
ANI Pharmaceuticals Inc (ANIP) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether ANI Pharmaceuticals Inc (ANIP) looks expensive on cached numbers — not a short thesis.
Latest reported ANIP revenue for 2024-12-31 was $614.4M. Net income was -$18.5M. Revenue was up 26.2% from 2023-12-31 to 2024-12-31. ANIP currently screens at market cap $1.41B.
ANIP currently screens at market cap $1.41B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ANIP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ANIP stock page for the full model, not this heading.
Not investment advice.